Gupta Rajesh, Estrella Michelle M, Scherzer Rebecca, Brewster Pamela S, Dworkin Lance D, Nguyen Hanh T, Xie Yanmei, Ix Joachim H, Shlipak Michael G, Murphy Timothy P, Cutlip Donald E, Lewis Eldrin F, Cooper Christopher J
Division of Cardiovascular Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH.
Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH.
Kidney Med. 2024 Dec 17;7(2):100948. doi: 10.1016/j.xkme.2024.100948. eCollection 2025 Feb.
RATIONALE & OBJECTIVE: Although renal artery stenosis (RAS) and heart failure (HF) have been linked, the incidence and predictors of HF among patients with RAS are not well described.
Post hoc analysis of the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) multicenter, open-label, randomized controlled trial (RCT).
Patients with atherosclerotic RAS and elevated blood pressure, chronic kidney disease, or both, and without a history of HF at enrollment.
Medical therapy alone versus medical therapy plus renal artery stenting.
Incident HF events.
This analysis included 808 participants enrolled in the CORAL trial without evidence of baseline HF. During a median follow-up of 4.8 years, 54 participants (6.7%) developed incident HF. HF incidence rates did not differ by randomized intervention (HR, 0.84; 95% confidence interval [CI], 0.49-1.43 for stent arm with medical arm as reference). Baseline diabetes (subdistribution hazard ratio (sHR), 2.07; 95% CI, 1.20-3.58), albuminuria (sHR, 1.12 per doubling of urinary albumin-creatinine ratio, 95% CI, 1.02-1.24), lower eGFR (sHR, 0.78 per 10 mL/min/1.73 m estimated glomerular filtration rate calculated with cystatin C and creatinine, 95% CI, 0.69-0.88), and peripheral vascular disease (PVD) (sHR, 2.18, 95% CI, 1.21-3.91) were independent predictors of incident HF. Participants who experienced incident HF had greater kidney function decline before HF events.
This is a post hoc analysis of a RCT. The number of HF events is small.
In patients with RAS, rates of incident HF did not differ between participants randomized to optimal medical therapy alone versus optimal medical therapy plus renal artery stenting. The presence of diabetes, PVD, and worse kidney health at baseline were associated with future HF events.
尽管肾动脉狭窄(RAS)与心力衰竭(HF)有关联,但RAS患者中HF的发病率及预测因素尚未得到充分描述。
对肾动脉粥样硬化病变的心血管结局(CORAL)多中心、开放标签、随机对照试验(RCT)进行事后分析。
患有动脉粥样硬化性RAS且血压升高、患有慢性肾病或两者兼具,且入组时无HF病史的患者。
单纯药物治疗与药物治疗加肾动脉支架置入术。
新发HF事件。
该分析纳入了CORAL试验中808名无基线HF证据的参与者。在中位随访4.8年期间,54名参与者(6.7%)发生了新发HF。随机干预组的HF发病率无差异(风险比[HR],0.84;95%置信区间[CI],以药物治疗组为参照,支架置入组为0.49 - 1.43)。基线糖尿病(亚组风险比[sHR],2.07;95% CI,1.20 - 3.58)、蛋白尿(sHR,尿白蛋白 - 肌酐比值每翻倍,sHR为1.12,95% CI,1.02 - 1.24)、较低的估算肾小球滤过率(eGFR)(sHR,使用胱抑素C和肌酐计算的估算肾小球滤过率每降低10 mL/min/1.73m²,sHR为0.78,95% CI,0.69 - 0.88)以及外周血管疾病(PVD)(sHR,2.18,95% CI,1.21 - 3.91)是新发HF的独立预测因素。发生新发HF的参与者在HF事件发生前肾功能下降更明显。
这是对一项RCT的事后分析。HF事件数量较少。
在RAS患者中,随机接受单纯最佳药物治疗与最佳药物治疗加肾动脉支架置入术的参与者之间,新发HF的发生率无差异。基线时存在糖尿病、PVD以及肾脏健康状况较差与未来HF事件相关。